---
title: "NG00087 – WashU2 GWAS"
id: "7727"
type: "dataset"
slug: "ng00087"
published_at: "2025-01-21T21:38:38+00:00"
modified_at: "2026-07-31T20:13:52+00:00"
url: "https://dss.niagads.org/datasets/ng00087/"
markdown_url: "https://dss.niagads.org/datasets/ng00087.md"
excerpt: "To access this data, please log into DSS and submit an application.Within the application, add this dataset (accession NG00087) in the “Choose a Dataset” section.Once approved, you will be able to log in and access the data within the DARM..."
taxonomy_dataset_categories:
  - "AD"
  - "Controlled Access"
  - "Data Type"
  - "Disease"
  - "Genotyping SNP Array"
  - "Illumina OmniExpress"
  - "Imputation"
  - "Open and Controlled Access Data"
  - "Platform"
  - "TOPMed r2"
---

## Overview

To access this data, please log into DSS and submit an application.  
Within the application, add this dataset (accession NG00087) in the “Choose a Dataset” section.  
Once approved, you will be able to log in and access the data within the DARM portal.

This dataset was originally published on the NIAGADS archive site and was moved to DSS on 06/18/2026.

#### Description

WashU2 GWAS is an SNP array dataset which contains AD cases and controls collected by the Knight Alzheimer’s Disease Research Center (ADRC) at Washington University. It consists of 38 cases, 94 healthy controls, and 103 other subjects that were used in analyses for this study. Participants were recruited as part of a longitudinal study of healthy aging and dementia. Diagnosis of dementia etiology was made in accordance with standard criteria and methods. Severity of dementia was assessed using the Clinical Dementia Rating scale. The dataset was analyzed within the stage 1 discovery dataset in the IGAP Kunkle et al. (2019) publication. Provided here are the PLINK genotype files that have undergone ADGC quality control procedures, covariates formatted by ADGC to be used with the genotype data, and imputation files (.bgen format) generated using the TOPMED-r2 reference panel.

#### Sample Summary per Data Type

| Sample Set | Accession | Data Type | Number of Samples |
| --- | --- | --- | --- |
| WashU2 GWAS | snd10130 | Genotyping SNP Array | 235 |

#### Available Filesets

| Name | Accession | Latest Release | Description |
| --- | --- | --- | --- |
| WashU2 GWAS: Genotype, covariate, and imputation files | fsa000156 | NG00087.v1 | Genotype, covariate, and imputation files |

View the [File Manifest](https://st1.niagads.org/portal/download-public/NG00087.v1/fm)
 for a full list of files released in this dataset.

## Participant Information

For a breakdown of the study population characteristics, navigate to the individual sample sets below.

| Sample Set | Accession Number | Number of Participants | Number of Samples |
| --- | --- | --- | --- |
| WashU2 GWAS | snd10130 | 235 | 235 |

## Related Studies

- [sa000008 - Charles F. and Joanne Knight Alzheimer's Disease Research Center (Knight ADRC)](https://dss.niagads.org/studies/sa000008/) The search for novel risk factors for Alzheimer disease relies on access to accurate and deeply phenotyped datasets. The Memory and Aging Project at the Knight-ADRC (Knight ADRC-MAP) collects plasma,… [Learn more](https://dss.niagads.org/studies/sa000008/)

## Cohorts

| Cohort | Number of Participants | Number of Samples |
| --- | --- | --- |
| Knight Alzheimer’s Disease Research Center (KGAD) | 235 | 235 |

## Consent Levels

| Consent Level | Number of Participants | Number of Samples |
| --- | --- | --- |
| DS-ADRD-IRB-PUB | 235 | 235 |

Visit the [Data Use Limitations page](/documentation/policies-and-guidelines/data-use-limitations/)
 for definitions of the consent levels above.

## Acknowledgement

### Acknowledgment statement for any data distributed by NIAGADS:

Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.

Use the study-specific acknowledgement statements below (as applicable):

### For investigators using any data from this dataset:

Please cite/reference the use of NIAGADS data by including the accession [NG00087](https://archive.niagads.org/datasets/NG00087)
.

### For investigators using Charles F. and Joanne Knight Alzheimer’s Disease Research Center (Knight ADRC) (sa000008) data:

This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501 and R01AG057777). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.

We thank the contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, and the Departments of Neurology and Psychiatry at Washington University School of Medicine.

**See below for additional dataset specific acknowledgments:**

*For use of the ADSP-PHC harmonized phenotypes deposited within dataset, ng00067, use the following statement:*

The Memory and Aging Project at the Knight-ADRC (Knight-ADRC), supported by NIH grants R01AG064614, R01AG044546, RF1AG053303, RF1AG058501, U01AG058922 and R01AG064877 to Carlos Cruchaga. The recruitment and clinical characterization of research participants at Washington University was supported by NIH grants P30AG066444, P01AG03991, and P01AG026276. Data collection and sharing for this project was supported by NIH grants RF1AG054080, P30AG066462, R01AG064614 and U01AG052410. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: [https://neurogenomics.wustl.edu/](https://neurogenomics.wustl.edu/)
) and the Departments of Neurology and Psychiatry at Washington University School of Medicine.

*For use of ng00050 and ng00052, use the following statement:*  
This work was supported by Pfizer and grants from the National Institutes of Health (R01-AG044546, P01-AG003991), and the Alzheimer's Association (NIRG-11–200110). This research was conducted while Carlos Cruchaga was a recipient of a New Investigator Award in Alzheimer's disease from the American Federation for Aging Research. Carlos Cruchaga is a recipient of a BrightFocus Foundation Alzheimer's Disease Research Grant (A2013359S). The recruitment and clinical characterization of research participants at Washington University were supported by NIHP50 AG05681, P01 AG03991, and P01 AG026276. Some of the samples used in this study were genotyped by the ADGC and GERAD. ADGC is supported by grants from the NIH (#U01AG032984) and GERAD from the Wellcome Trust (GR082604MA) and the Medical Research Council (G0300429). Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec; Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace; Merck; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Rev December 5, 2013 Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org/)
). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

## Publications

- Kunkle BW. **Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.***Nature genetics. 2019 Mar.*[PubMed link](https://pubmed.ncbi.nlm.nih.gov/30820047/)

## Approved Users

**Total number of approved DARs:** 1

[JSON Export](https://st1.niagads.org/portal/v1/adars/NG00087)
|[CSV Export](https://dss.niagads.org/wp-admin/admin-post.php?action=niagads_export_dars_csv&accession=NG00087)

- Investigator: Blue, Elizabeth Institution: University of Washington Project Title: Genetic modifiers of Alzheimer's disease Date of Initial Approval: July 15, 2025 Current Status: Approved Publications: None Reported Research Use Statements: Show statements Technical Research Use Statement: The objective of the proposed research is to identify and characterize genetic variants involved in Alzheimer's disease (AD) risk and AD-related phenotypes to ultimately identify potential avenues for therapeutic approaches and prevention of the disease. Our study design will use phenotypic (ex., AD diagnosis, age-at-onset, APOE genotype) and genomic data (ex., WGS, array, imputed genotypes) from NIAGADS studies to investigate genotype-phenotype associations. Strategies include association testing and haplotype- and family-based approaches, including estimates of relatedness and population genetics analyses as needed to perform the association testing (ex. control for population structure). NIAGADS data will not be used to investigate individual identity. Consent type and other Data Use Limitations (DUL) for each study will be respected in all analyses. Data from an individual with disease-specific consent will not be used in analyses outside of that restriction, including indirect uses such as imputation reference panels or variant summary statistics. When an individual’s DUL prohibits investigation of population genetics, population history or related issues, their data will be excluded from studies that address those issues. We intend to publish or otherwise broadly share any findings from this study with the scientific community. As such, genomic summary results from datasets with a “sensitive” designation will only be shared through publications to support study’s conclusions and through NIH-funded data repositories which maintain restricted access (ex. NIAGADS). Data from NIAGADS may be combined with non-NIAGADS data from the same or other studies (obtained from dbGaP or other sources), to improve the power for novel genetic discoveries, while respecting the consent of all participants. We expect that this activity creates no additional risks to participants. Data will be shared only among Internal Collaborators at the University of Washington. We do not plan to collaborate with External Collaborators at other institutions. Non-Technical Research Use Statement: We propose to identify and characterize genetic variation involved in Alzheimer's disease (AD), providing insight as to why some individuals develop or avoid AD, and ultimately identifying potential avenues for therapeutic approaches and prevention of the disease. We will combine phenotype and genotype data using association testing and haplotype- and family-based approaches to identify and characterize associations and refine those signals with fine-mapping tools and external data.

### Total number of participants: 235

SexRaceEthnicityDiagnosisAPOE

Female6628.1 %

Male6628.1 %

Sex not reported: 103 (43.8%)

| White | 132 |
| --- | --- |
| NA | 103 |

- 2312 (5.1%)
- 243 (1.3%)
- 3373 (31.1%)
- 3436 (15.3%)
- 447 (3.0%)
- NA104 (44.3%)

| AD |  |  |
| --- | --- | --- |
| Control | 94 | 40.0% |
| Case | 38 | 16.2% |
| Unknown | 103 | 43.8% |

Not Hispanic or Latino

132

56.2%

Not Applicable/Not Available

103

43.8%